89bio's pegozafermin could be major player in the dyslipidemia market

17 January 2023

California, USA-based clinical-stage biopharmaceutical company 89bio’s (Nasdaq: ETNB) pegazofermin has potential to become one of the major players in the dyslipidemia space if it is successful in Phase III clinical trials, says data and analytics firm GlobalData.

The Food and Drug Administration (FDA) recently supported the advancement of pegozafermin into two Phase III clinical trials, the first due to launch in the first half of 2023. If successful, pegozafermin has potential to address an unmet need of efficacious therapies with improved side-effect profiles for hypertriglyceridemia. According to the analyst consensus forecast on the GlobalData Pharma Intelligence Center, the drug is expected to reach $438 million by 2028. Pegozafermin is currently the only drug being investigated by 89bio and is also in Phase II trials for non-alcoholic steatohepatitis (NASH).

Earlier this month, 89bio said that, based on the results from its previous trials and recent data from other NASH product candidates, it remains confident that the trial outcome could support the transition into Phase III.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK